Protalix BioTherapeutics, Inc. Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature
Protalix BioTherapeutics, Inc. (PLX) reported Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature of $1.31 million for the 9-month period ending 2017-09-30, per its 10-Q filed 2019-03-18.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature · last filed 2019-03-18
- 2017-09-30: Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month $1.31M.
| Period end | Adjustments to Additional Paid in Capital, Convertible Debt with Conversion Feature 9 month |
|---|---|
| 2017-09-30 | $1.31M 10-Q · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |